25 active not recruiting, 17 recruiting, 14 completed, 10 terminated. 76 Phase 2, 13 Phase 1, 6 Phase 3.
Follow deltacortene: new trials by email Literature Review of deltacortene trials Research Report on deltacortene
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 / Phase 3 | Not yet recruiting | ECOG-ACRIN Cancer Research Group | 432 | 2027-01-06 | 2026-10-01 |
| Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma Biospecimen Collection, Bone Marrow Biopsy, Carboplatin - Recurrent Burkitt Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements | Phase 2 / Phase 3 | Not yet recruiting | National Cancer Institute (NCI) | 271 | 2026-10-30 | 2026-08-19 |
| Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Adult Burkitt Lymphoma | Phase 2 | Not yet recruiting | AIDS Malignancy Consortium | 43 | 2026-09-17 | 2026-10-16 |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate - Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 2 | Recruiting | Mayo Clinic | 202 | 2026-08-04 | 2026-09-18 |
| Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Bone Marrow Collection - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, T Acute Lymphoblastic Leukemia | Phase 2 | Suspended | University of Washington | 30 | 2026-05-08 | 2026-09-29 |
| Dose-Adjusted EPOCH With or Without Rituximab Plus Ponatinib for the Treatment of Newly-Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia/Lymphoma Cyclophosphamide, Doxorubicin, Etoposide - B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Lymphoblastic Leukemia/Lymphoma With t(9;22)(q34.1;q11.2); BCR-ABL1 | Phase 2 | Recruiting | University of Washington | 33 | 2026-03-30 | 2026-08-13 |
| Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma | Phase 2 | Recruiting | University of Washington | 18 | 2025-12-07 | 2026-10-21 |
| Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - High Grade B-Cell Lymphoma With MYC and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2025-10-07 | 2026-10-21 |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia Asparaginase Erwinia chrysanthemi, Biospecimen Collection, Blinatumomab - Acute Leukemia of Ambiguous Lineage, B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 153 | 2025-06-05 | 2026-10-27 |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) Biospecimen Collection, Blinatumomab, Bone Marrow Biopsy - B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 222 | 2025-05-30 | 2026-10-27 |
| Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 16 | 2024-07-24 | 2026-10-14 |
| Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma Biopsy, Biospecimen Collection, Bone Marrow Aspiration and Biopsy - Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma | Phase 1 / Phase 2 | Recruiting | OHSU Knight Cancer Institute | 40 | 2024-06-13 | 2026-07-07 |
| Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial Abiraterone, Apalutamide, Biospecimen Collection - Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer | Phase 2 | Recruiting | Mayo Clinic | 532 | 2024-06-03 | 2026-07-20 |
| CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations Abiraterone Acetate/Niraparib, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma | Phase 2 | Terminated | Mayo Clinic | 8 | 2024-03-05 | 2026-07-22 |
| A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia Biospecimen Collection, Bone Marrow Aspiration, Calaspargase Pegol - Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia | Phase 2 | Active not recruiting | Children's Oncology Group | 78 | 2024-01-08 | 2026-08-25 |
| Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer Abiraterone, Biospecimen Collection, Darolutamide - Advanced Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8 | Phase 2 | Recruiting | University of California, Davis | 75 | 2023-11-09 | 2026-03-13 |
| Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma Cyclophosphamide, Doxorubicin, Etoposide - Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | Phase 2 | Active not recruiting | University of California, Davis | 24 | 2023-05-24 | 2026-09-28 |
| Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia Cyclophosphamide, Doxorubicin, Etoposide - B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative | Phase 2 | Active not recruiting | University of Washington | 32 | 2023-03-27 | 2026-05-11 |
| Rituximab, Lenalidomide, Acalabrutinib, Tafasitamab Alone and With Combination Chemotherapy for the Treatment of Newly Diagnosed Non-germinal Center Diffuse Large B-Cell Lymphoma, Smart Stop Study Acalabrutinib, Cyclophosphamide, Doxorubicin Hydrochloride - Diffuse Large B-Cell Lymphoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 62 | 2022-03-03 | 2026-10-06 |
Showing 20 of 76. Sign in to see all of them.
Prostatic Neoplasms (21) · Burkitt Lymphoma (17) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (12) · Lymphoma, Large B-Cell, Diffuse (11) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (8) · Lymphoma, B-Cell (4) · Blast Crisis (2) · Enteropathy-Associated T-Cell Lymphoma (2) · Immunoblastic Lymphadenopathy (2) · Leukemia, Biphenotypic, Acute (2) · Lymphoma (2) · Lymphoma, Follicular (2) · Lymphoma, Large-Cell, Anaplastic (2) · Lymphoma, T-Cell (2) · Plasmablastic Lymphoma (2)
M.D. Anderson Cancer Center (21) · National Cancer Institute (NCI) (16) · University of Washington (9) · Children's Oncology Group (3) · Mayo Clinic (3) · OHSU Knight Cancer Institute (3) · University of California, Davis (3) · City of Hope Medical Center (2) · Northwestern University (2) · AIDS Malignancy Consortium (1) · Academic and Community Cancer Research United (1) · Andres J. M. Ferreri (1) · David Bond, MD (1) · ECOG-ACRIN Cancer Research Group (1) · European Myeloma Network B.V. (1)
United States (69) · Canada (5) · Puerto Rico (4) · Australia (3) · Italy (3) · Israel (2) · New Zealand (2)
Elias Jabbour (4) · Christopher Logothetis (2) · Farhad Ravandi-Kashani (2) · Mamta Parikh (2) · Michael Schweizer (2) · Ryan D. Cassaday (2) · Alex F Herrera (1) · Ana Aparicio (1) · Anjali S Advani (1) · Ariela Noy (1) · Bagi Jana, MD (1) · Barbara Pro, MD (1) · Benjamin Maughan, MD (1)
PMID 35952327, PMID 39319495, PMID 20466853, PMID 25628469, PMID 26432046, PMID 29261439, PMID 29360414, PMID 29531316, PMID 29618479, PMID 29812996, PMID 30501869, PMID 31221778, PMID 32430507, PMID 32946355, PMID 33191168, PMID 33242441, PMID 34634256, PMID 34686472, PMID 35622074, PMID 36279879, PMID 36322825, PMID 36521030, PMID 36600670, PMID 36841758, PMID 37505794, PMID 38207208, PMID 38237077, PMID 39067464, PMID 40135712, PMID 40706069, PMID 40802906, PMID 41202201, PMID 41671463, PMID 42117295, PMID 42305039, PMID 42660130
U10CA180886 (5), U10CA180888 (5), P30CA015704 (4), U10CA180820 (4), P30CA016672 (3), P30CA093373 (3), P30CA033572 (2), P30CA060553 (2), U10CA021115 (2), U10CA032102 (2), U10CA098543 (2), U10CA180821 (2), UM1CA121947 (2), UM1CA186691 (2), N01CM00038 (1)